(Total Views: 340)
Posted On: 10/29/2020 3:25:55 PM
Post# of 36568
Yes, it certainly seems clean. In addition to your $84 cash on hand, I was noticing that expenditures were around $305 for the year.
I thought this was interesting, from page 29:
Our only ongoing research and development projects is the Phase II clinical study using AE37 in combination with pembrolizumab (Keytruda ®) for treatment of metastatic triple negative breast cancer.
On July 7, 2020 we entered into an agreement with Ajinmoto Bio-Pharma Services (“Ajin”) under which Ajin will manufacture one cGMP batch of AE 37. We may cancel the agreement by providing Ajin written notice. If we cancel the project we will be subject to cancellation fees and be required to reimburse Ajin’s unbilled costs prior to the effective date of the cancellation. The estimated total payments required under this agreement are $243,900, including shipping and material estimates, of which Ajin has billed us $121,450. We have included cost related to this agreement in research and development in our statement of operations for the year ended July 31, 2020.
So they are trying to get some AE37 on-hand, presumably for trials (?). That can't be a bad thing...
I thought this was interesting, from page 29:
Our only ongoing research and development projects is the Phase II clinical study using AE37 in combination with pembrolizumab (Keytruda ®) for treatment of metastatic triple negative breast cancer.
On July 7, 2020 we entered into an agreement with Ajinmoto Bio-Pharma Services (“Ajin”) under which Ajin will manufacture one cGMP batch of AE 37. We may cancel the agreement by providing Ajin written notice. If we cancel the project we will be subject to cancellation fees and be required to reimburse Ajin’s unbilled costs prior to the effective date of the cancellation. The estimated total payments required under this agreement are $243,900, including shipping and material estimates, of which Ajin has billed us $121,450. We have included cost related to this agreement in research and development in our statement of operations for the year ended July 31, 2020.
So they are trying to get some AE37 on-hand, presumably for trials (?). That can't be a bad thing...
(1)
(0)
